Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations

Nektar Therapeutics (NKTR)

18.31   0.3 (1.67%) 11-19 16:00
Open: 18.14 Pre. Close: 18.01
High: 18.46 Low: 17.9237
Volume: 1,602,485 Market Cap: 3221M
Nektar Therapeutics Inc is a biopharmaceutical company engaged in the development of new molecules to treat diseases with unmet medical needs. The company's research and development activities involve small-molecule drugs, and peptides.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 18.476 - 18.606 18.606 - 18.707
Low: 17.678 - 17.815 17.815 - 17.922
Close: 18.13 - 18.343 18.343 - 18.509

Technical analysis

as of: 2019-11-19 4:28:32 PM
Stoxline posted a SELL today, same as yesterday. Downward movement continues.
Target: Six months: 23.48     One year: 26.26
Support: Support1: 16.26    Support2: 13.53
Resistance: Resistance1: 20.10    Resistance2: 22.48
Pivot: 18.90
Moving Average: MA(5): 19.07     MA(20): 18.44
MA(100): 22.12     MA(250): 30.66
MACD: MACD(12,26): 0.31     Signal(9): 0.32
Stochastic oscillator: %K(14,3): 34.08     %D(3): 43.19
RSI: RSI(14): 48.15
52-week: High: 47.11  Low: 15.64  Change(%): -52.0
Average Vol(K): 3-Month: 352878  10-Days: 341908

Price, moving averages and Bollinger Bands

Price and moving averages has closed below its Short term moving average. Short term moving average is currently above mid-term; AND below long term moving averages. From the relationship between price and moving averages; we can see that: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.
NKTR has closed above bottom band by 36.2%. Bollinger Bands are 30.9% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Headline News

Nektar Therapeutics (NASDAQ:NKTR) Price Target Increased to $24.00 by Analysts at Canaccord Genuity
Nektar Therapeutics (NASDAQ:NKTR) had its price target raised by Canaccord Genuity from $20.00 to $24.00 in a research report sent to investors on Tuesday, The Fly reports. Canaccord Genuity currently has a buy rating on the biopharmaceutical company’s stock. A number of other analysts also recently issued reports on the stock. BidaskClub downgraded shares of […]

Nektar Therapeutics Stock Is Rising on Test Data for Cancer Drug
Nektar Therapeutics released clinical data that raised hope about a drug-development program that has encountered manufacturing problems.

Financial Analysis

Growth measures the growth of both a company's revenue and net income. it tells investors how fast a company is growing.
Profitability measures a company’s ability to generate earnings as compared to its expenses and other relevant costs.
Solvency measures a company's ability to meet its long-term debts. Acceptable solvency ratios will vary from industry to industry.
Efficiency measures the strength of a company's return on invested capital. It can identify business that are better managed or not.
Click here to get more fundamental analysis.
Tweet this page Share on Facebook
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  Nasdaq Global Select
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. (M) 175.92
Shares Float (M) 174.29
% Held by Insiders 0.88
% Held by Institutions 96.18
Shares Short (K) 30900
Shares Short P. Month (K)

Stock Financials

EPS -2.440
Book Value (p.s.) 8.470
PEG Ratio 1.04
Profit Margin
Operating Margin -357.18
Return on Assets (ttm) -12.4
Return on Equity (ttm) -26.0
Qtrly Rev. Growth 5.2
Gross Profit (p.s.) 6.651
Sales Per Share
EBITDA (p.s.) -2.376
Qtrly Earnings Growth
Operating Cash Flow (M) -321.01
Levered Free Cash Flow (M) -207.73

Stock Valuations

P/E -7.50
P/E Growth Ratio 0.02
P/BV 2.16
P/S 26.53
P/CF -10.03

Dividends & Splits

Dividend Yield
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Forward Dividend
Last Split Date
Last Split Ratio -1e+010
7 Binary Options
Your Ad Here
Stock Chart
Stoxline Lite
Stoxline Pro
Option Calculator
(c) 2006-2019 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.